Common use of CBK Sci Con Limited Clause in Contracts

CBK Sci Con Limited. CBK’s key contributions to the project include support for project management, where CBK works as an integral part of the project management team at UCL providing complementary experience from commercial industry perspectives alongside UCL’s research management expertise. CBK is the lead partner co-ordinating the project’s quality assurance planning, data management planning and the final public reporting. The project quality assurance system and its procedures were developed with all core partners under CBK’s lead during the first 6 months of the project, as was the project’s approach to data management. Both areas were formally reported at this time. As a partner in the team supporting the management of dissemination activities, CBK has developed the CompBioMed online presence principally via a unique website created for the project. The website has both external and internal access facilities and functions that facilitate the storage of key documents and dynamic interchange of project information to partners and to the public. All configurable documents are stored in their latest form in an “intranet” section of the website with viewing access enabled for the core partners. There is progressively less restricted access to facilitate the engagement of wider stakeholders in science and medicine, through to direct engagement with the public via news, events (& booking) and a knowledgebase. The project website was set up before the project started with the website release deliverable (D3.1) submitted at M3 detailing the public release of the website. The functionality of the website is regularly reviewed and developed as its use increases and the project output information builds. CBK has a substantial presence in the overall dissemination and closely related training team. The company led the team in the development of the plan for dissemination, the public plan being published at the 3-month point. Subsequently CBK has led and continues to lead the co-ordination of the dissemination activities and produces all materials necessary in support of these activities. This has resulted in substantial success in promulgating the results and knowhow to a wider scientific and public community. Where seen to be beneficial, CBK has co-ordinated the application of additional effort to achieve a significant boost to the dissemination of project information. A key example of this is the development of a film showing the state of the art of HPC use in biomedicine, that formed the basis of an IMAX cinema showing to the public at the Science Museum in London in 2017. This film and the material captured in recording the event is now being further developed for wider distribution at science orientated public events. The project training plan was developed early in the project and CBK is one of the core partners involved in the coordination of training activities, including help with workshop materials, facilities and organising events. The management of innovation is led by the University of Edinburgh and CBK is a partner in the innovation management team, also providing one of its directors to sit on the Innovation Advisory Board. CBK led the development of the plan for managing the processes within the project aimed at supporting the scientific research teams to best exploit the project results for maximum impact. The formal plan was issued 6 months into the project and encompasses the project’s approach to identifying new knowhow and tools and then providing support in assessing their exploitation potential, whether this be academic, societal or commercial potential. To date this support has taken the form of advice for specific exploitation routes, enhanced dissemination to appropriate stakeholder groups, commercial advice for software commercialisation and early help in assessing how knowhow may be bundled to support provision of consultancy services. In addition, a specific new training module which serves to educate medical students in the use of HPC simulation is currently being assessed for its commercial potential. The project has a task which focuses on incubator coordination. Bringing its experience of university incubation and acceleration, CBK contributed to the development of the approach which aims to facilitate collaborations between research partners and commercialisation parties for results which have a high commercial growth potential. LifeTec Group (LTG) is playing a substantial role in our Innovation and Sustainability work package, particularly in the future precommercial activities. The main tasks of LTG in this project are the development and application of cardiovascular in silico models and tools and to combine them with the models of other participants, to create workflows, pipelines and interfaces. LTG is involved in business development for the ▇▇▇ by working on the Innovation Plan, which established mechanisms to actively promote in silico methods to e.g. the pharmaceutical industry. The Innovation Plan is a live document which is maintained throughout the life of our Centre. Further, LTG is also contributing to the development of the sustainability plan to ensure the Centre adheres to in silico regulatory procedures (FDA for US and EMA for EU) and incorporates relevant regulatory procedures into the ▇▇▇’▇ portfolio. LTG have explored some of the cardiovascular software models that are available within the consortium. Discussions with clinicians have been held to explore their interest and needs for a cardiovascular simulation tool that they would be beneficial to the clinical decision-making process as well as allows for an exploitation opportunity towards the end of the project. To date, LTG has envisioned a tool to provide clinical decision support as a service, based upon the infrastructure currently provided by CompBioMed. More specifically, discussions with clinicians have identified a challenge in the decision-making process to treat difficult coronary stenosis either by bypass surgery or by placing a stent. A simulation that can predict the outcome of both interventions as well as present the accuracy of said prediction, would be very helpful in the decision-making process and would reduce the cost of treating complications. The idea is that relatively (computationally) cheap 1D models with input from patient specific data will provide quick results of both interventional strategies, and that running many cases in parallel allows for a population of results that not only provides a result but also an assessment of the expected accuracy of the result. The 1D models may also be used as a tool to provide inlet or outlet boundary conditions for more complex 3D cardiovascular models, such as to incorporate such 3D local simulations into a larger vascular computational environment. Collaborations with consortium partners on such interactions will be beneficial for the integration of different software tools. Acellera is playing a substantial role in three work packages, namely Biomedical Research Activities (WP2), Innovation and Sustainability (WP4), and Empowering Biomedical Applications (WP6). Acellera provide technology and knowhow for large- scale molecular simulations and analysis. They participate in the following research activities within the Molecular-based Medicine theme: Molecular simulation of the transport properties and mechanism of gating, to decipher the key factors controlling selectivity; Fragment-based drug design for GPCR targets; rational antibody design for EGFR inhibitors. Since the beginning of the project, Acellera participated in the dissemination of the project news and promoted the use of in silico methods in Industry and non-profit entities by participating and organising events, but especially by its effective marketing activity. This activity is illustrated by the organisation of workshops, its participation in the winter school (at BSC (14-16 February 2018, Barcelona)), and the organisation of exclusive webinars for CompBioMed partners as well as for our customers. Strong in its expertise in biomolecular interactions, Acellera developed innovative methods to predict small molecule interaction with protein target, especially with GPCR, in the following publication: • Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs, Sci. Rep. 2018; 8:897. Acellera’s ISBA protocol has been optimized and is ready to initiate collaboration among CompBioMed partners. Moreover, they provide free access through its platform ▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ to promote the use of in silico methods for drug discovery and molecular medicine projects. Finally, ▇▇▇▇▇▇▇▇ has produced the following seven CompBioMed-related publications since the start of our Centre. • ▇. ▇▇▇▇▇▇, ▇. ▇▇▇▇▇, M. A. ▇▇▇▇▇▇-▇▇▇▇▇▇▇, ▇. ▇▇▇, ▇. ▇▇▇▇, ▇. ▇. ▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇, T. T. ▇▇▇▇▇, ▇. ▇▇▇, ▇. ▇▇▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇ and ▇. ▇▇ ▇▇▇▇▇▇▇▇▇, Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs in Sci. Rep., 2018, 8, Article number: 897, DOI: 10.1038/s41598-018-19345-7

CBK Sci Con Limited. CBK’s key contributions to the project include support for project management, where CBK works as an integral part of the project management team at UCL providing complementary experience from commercial industry perspectives alongside UCL’s research management expertise. CBK is the lead partner co-ordinating the project’s quality assurance planning, data management planning and the final public reporting. The project quality assurance system and its procedures were developed with all core partners under CBK’s lead during the first 6 months of the project, as was the project’s approach to data management. Both areas were formally reported at this time. As a partner in the team supporting the management of dissemination activities, CBK has developed the CompBioMed online presence principally via a unique website created for the project. The website has both external and internal access facilities and functions that facilitate the storage of key documents and dynamic interchange of project information to partners and to the public. All configurable documents are stored in their latest form in an “intranet” section of the website with viewing access enabled for the core partners. There is progressively less restricted access to facilitate the engagement of wider stakeholders in science and medicinepresence, through to direct engagement with the public via news, events (& booking) and a knowledgebase. The project website was set up before the project started with the website release deliverable (D3.1) submitted at M3 detailing the public release of the website. The functionality of the website is regularly reviewed and developed as its use increases and the project output information builds. CBK has a substantial presence in the overall dissemination and closely related training team. The company led the team Centre in the development of the plan for dissemination, the public plan being published at the 3-month point. Subsequently CBK has led and continues to lead the co-ordination of the dissemination activities and produces all materials necessary in support of these activities. Public reports on all training and dissemination activities have been produced in September 2017 and in March 2018. This has resulted in substantial success in promulgating the results and knowhow to a wider scientific and public community. Where seen to be beneficial, CBK has co-ordinated the application of additional effort to achieve a significant boost to the dissemination of project information. A key example of this is the development of a film showing the state of the art of HPC use in biomedicine, [2], that formed the basis of an IMAX cinema showing to the public at the Science Museum in London in 2017, [3, 4]. This film and the material captured in recording the event is now being has been further developed for wider distribution at science science-orientated public events. In June 2018 the film was shown at the Cheltenham Science Festival and again a panel session was held with the public audience of over 200 people. The project training plan was developed early in the project and CBK is one of the core partners involved in the coordination of training activities, including help with workshop materials, facilities and organising events. The management of innovation is innovation, led by the University of Edinburgh and Edinburgh, includes CBK is as a partner in on the innovation management team, team and CBK also providing provides one of its directors to sit on the Innovation Advisory Board. CBK led the development of the plan for managing the processes within the project aimed at supporting the scientific research teams to best exploit the project results for maximum impact. The formal plan was issued 6 months into the project and encompasses the project’s approach to identifying new knowhow and tools and then providing support in assessing their exploitation potential, whether this be academic, societal or commercial potential. To date this support has taken the form of advice for specific exploitation routes, enhanced dissemination to appropriate stakeholder groups, commercial advice for software commercialisation and early help in assessing how knowhow may be bundled to support provision of consultancy services. In addition, a specific new training module which serves to educate medical students in the use of HPC simulation is currently being assessed for its commercial potential. The project has a task which focuses on incubator coordination, namely T4.2 Incubator Coordination, which is led by SURFsara. Bringing its experience of university incubation and acceleration, CBK contributed to the development of the approach which aims to facilitate collaborations between research partners and commercialisation parties for results which have a high commercial growth potential. LifeTec Group (LTG) is playing a substantial role in our Innovation and Sustainability work package, particularly in the future precommercial activities. The main tasks of LTG in this project are the development and application of cardiovascular in silico models and tools and to combine them with the models of other participants, to create workflows, pipelines and interfaces. LTG is involved in business development for the ▇▇▇ by working on the Innovation Plan, which established mechanisms to actively promote in silico methods to e.g. the pharmaceutical industry. The Innovation Plan is a live document which is maintained throughout the life of our Centre. Further, LTG is also contributing to the development of the sustainability plan to ensure the Centre adheres to in silico regulatory procedures (FDA for US and EMA for EU) and incorporates relevant regulatory procedures into the ▇▇▇’▇ portfolio. LTG have explored some of the cardiovascular software models that are available within the consortium. Discussions with clinicians have been held to explore their interest and needs for a cardiovascular simulation tool that they would be beneficial to the clinical decision-making process as well as allows for an exploitation opportunity towards the end of the project. To date, LTG has envisioned a tool to provide clinical decision support as a service, based upon the infrastructure currently provided by CompBioMed. More specifically, discussions with clinicians have identified a challenge in the decision-making process to treat difficult coronary stenosis either by bypass surgery or by placing a stent. A simulation that can predict the outcome of both interventions as well as present the accuracy of said prediction, would be very helpful in the decision-making process and would reduce the cost of treating complications. The idea is that relatively (computationally) cheap 1D models with input from patient specific data will provide quick results of both interventional strategies, and that running many cases in parallel allows for a population of results that not only provides a result but also an assessment of the expected accuracy of the result. The 1D models may also be used as a tool to provide inlet or outlet boundary conditions for more complex 3D cardiovascular models, such as to incorporate such 3D local simulations into a larger vascular computational environment. Collaborations with consortium partners on such interactions will be beneficial for the integration of different software tools. Acellera is playing a substantial role in three work packages, namely Biomedical Research Activities (WP2), Innovation and Sustainability (WP4), and Empowering Biomedical Applications (WP6). Acellera provide technology and knowhow for large- scale molecular simulations and analysis. They participate in the following research activities within the Molecular-based Medicine theme: Molecular simulation of the transport properties and mechanism of gating, to decipher the key factors controlling selectivity; Fragment-based drug design for GPCR targets; rational antibody design for EGFR inhibitors. Since the beginning of the project, Acellera participated in the dissemination of the project news and promoted the use of in silico methods in Industry and non-profit entities by participating and organising events, but especially by its effective marketing activity. This activity is illustrated by the organisation of workshops, its participation in the winter school (at BSC (14-16 February 2018, Barcelona)), and the organisation of exclusive webinars for CompBioMed partners as well as for our customers. Strong in its expertise in biomolecular interactions, Acellera developed innovative methods to predict small molecule interaction with protein target, especially with GPCR, in the following publication: • Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs, Sci. Rep. 2018; 8:897. Acellera’s ISBA protocol has been optimized and is ready to initiate collaboration among CompBioMed partners. Moreover, they provide free access through its platform ▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ to promote the use of in silico methods for drug discovery and molecular medicine projects. Finally, ▇▇▇▇▇▇▇▇ has produced the following seven CompBioMed-related publications since the start of our Centre. • ▇. ▇▇▇▇▇▇, ▇. ▇▇▇▇▇, M. A. ▇▇▇▇▇▇-▇▇▇▇▇▇▇, ▇. ▇▇▇, ▇. ▇▇▇▇, ▇. ▇. ▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇, T. T. ▇▇▇▇▇, ▇. ▇▇▇, ▇. ▇▇▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇ and ▇. ▇▇ ▇▇▇▇▇▇▇▇▇, Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs in Sci. Rep., 2018, 8, Article number: 897, DOI: 10.1038/s41598-018-19345-7